HRP20230804T1 - Inhibitori izlučivanja proteina na bazi triazaciklododekansulfonamida ("tcd") - Google Patents
Inhibitori izlučivanja proteina na bazi triazaciklododekansulfonamida ("tcd") Download PDFInfo
- Publication number
- HRP20230804T1 HRP20230804T1 HRP20230804TT HRP20230804T HRP20230804T1 HR P20230804 T1 HRP20230804 T1 HR P20230804T1 HR P20230804T T HRP20230804T T HR P20230804TT HR P20230804 T HRP20230804 T HR P20230804T HR P20230804 T1 HRP20230804 T1 HR P20230804T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- continued
- compound
- salt according
- group
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000028327 secretion Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000003003 spiro group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- -1 preoxazolyl Chemical group 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (18)
1. Spoj Formule (I), ili njegova farmaceutski prihvatljiva sol:
[image]
pri čemu:
svako od Ra i Rb je neovisno H ili C1-3alkil;
R1 je H, OH, C1-3alkil, OC1-3alkil, =CH2, ili =NOR5; ili R1 je C3-6cikloalkil ili C3-6heterocikloalkil i formira spiro skupinu s prstenom ugljika na koji je spojena; svako od R1a i R1b je neovisno H ili C1-3alkil;
R2 je C3-9heterocikloalkil ili C3-9heterocikloalkenil, i nije morfolinil;
R3 sadrži C3-8cikloalkil, C3-8cikloalkenil, C3-7heterocikloalkil, C6-10aril, ili C2-6heteroaril;
R4 je C6-10aril, ili C2-6heteroaril;
svako R5 neovisno je H, C1-3alkil, ili C0-2alkilen-C6-10aril;
X je C1-3alkilen;
Y je SO ili SO2;
svaka heterocikloalkil, heterocikloalkenil, i heteroaril skupina neovisno ima 1, 2, ili 3 prstena heteroatoma izabrana prema N, O, i S.
2. Spoj ili sol prema patentnog zahtjeva 1, pri čemu svako Y je SO2.
3. Spoj ili sol prema patentnog zahtjeva 1 ili 2, pri čemu R1 je (1) CH3 ili OCH3 ili (2) C3-6cikloalkil ili C3-6heterocikloalkil i formira spiro skupinu sa prstenom ugljika na koji je spojeno.
4. Spoj ili sol prema patentnom zahtjevu 3, pri čemu R1 je CH3 i ispoljava S stereokemiju.
5. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1-4, pri čemu R2 sadrži oksetanil, azetidinil, tetrahidrofuranil, pirolidinil, tetrahidropiranil, piranil, piperidinil, piperazinil, azepanil, ili tetrahidropiridinil.
6. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1-4, pri čemu C3-7heterocikloalkil ili C3-7heterocikloalkenil iz R2 sadrži most ili spiro skupinu.
7. Spoj ili sol prema patentnog zahtjeva 5, pri čemu R2 je izabran od skupine koja sadrži
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
8. Spoj ili sol prema patentnom zahtjevu 7, pri čemu R2 je izabran od skupine koja sadrži
[image]
[image]
i
[image]
9. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1-8, pri čemu R3 sadrži ciklopropil, ciklobutil, ciklopentil, cikloheksil, ciklopentenil, cikloheksenil, tetrahidropiranil, fenil, pirolil, pirazolil, imidazolil, tetrazolil, furanil, tiofenil, tiazolil, oksazolil, premaoksazolil, oksadiazolil, tiadiazolil, piridinil, pirazinil, ili pirimidinil.
10. Spoj ili sol prema patentnom zahtjevu 9, pri čemu X-R3 je izabran od skupine koja sadrži
[image]
[image]
[image]
[image]
[image]
and-i
11. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1-10, pri čemu je R4 po izboru supstituirano s jednom do tri skupine neovisno izabrane od halo, C1-3alkil, C1-3alkoksi, C(O)N(RN)2, i N(RN)2, i svako RN je neovisno H ili C1-3alkil.
12. Spoj ili sol prema patentnom zahtjevu 11, pri čemu R4 je izabrano iz skupine koja sadrži
[image]
i
[image]
13. Spoj ili sol prema patentnom zahtjevu 1, pri čemu:
Ra, Rb, R1a, i R1b su svaka H; R1 je =CH2 ili CH3;
R2 je
[image]
[image]
[image]
X-R3 je
[image]
R4 je
[image]
i
i svako Y je SO2.
14. Spoj ili njegova farmaceutski prihvatljiva sol, koji ima strukturu izabranu od skupine koja sadrži:
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
15. Spoj ili sol prema patentnom zahtjevu 14, pri čemu taj spoj ima strukturu izabranu od skupine koja sadrži:
[image]
[image]
[image]
16. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1-15 za liječenje karcinoma.
17. Spoj za uporabu prema patentnom zahtjevu 16, pri čemu je karcinom melanom, multipli mijelom, karcinom prostate, karcinom pluća, karcinom pankreasa, karcinom skvamozne stanice, leukemija, limfom, neuroendokrini tumor, karcinom mjehura, ili karcinom debelog crijeva i rektuma.
18. Spoj za upotrebu prema patentnom zahtjevu 16, pri čemu je karcinom kruti tumor.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643931P | 2018-03-16 | 2018-03-16 | |
| US201962803704P | 2019-02-11 | 2019-02-11 | |
| PCT/US2019/022533 WO2019178510A1 (en) | 2018-03-16 | 2019-03-15 | Triazacyclododecansulfonamide ("tcd")-based protein secretion inhibitors |
| EP19715609.4A EP3765447B1 (en) | 2018-03-16 | 2019-03-15 | Triazacyclododecansulfonamide ("tcd")-based protein secretion inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230804T1 true HRP20230804T1 (hr) | 2023-11-10 |
Family
ID=66041635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230804TT HRP20230804T1 (hr) | 2018-03-16 | 2019-03-15 | Inhibitori izlučivanja proteina na bazi triazaciklododekansulfonamida ("tcd") |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11578055B2 (hr) |
| EP (1) | EP3765447B1 (hr) |
| JP (1) | JP2021518337A (hr) |
| KR (1) | KR20200133238A (hr) |
| CN (1) | CN112262129B (hr) |
| AU (1) | AU2019236248B2 (hr) |
| BR (1) | BR112020018767A2 (hr) |
| CA (1) | CA3093972A1 (hr) |
| CL (1) | CL2020002398A1 (hr) |
| CO (1) | CO2020012484A2 (hr) |
| DK (1) | DK3765447T3 (hr) |
| ES (1) | ES2953139T3 (hr) |
| FI (1) | FI3765447T3 (hr) |
| HR (1) | HRP20230804T1 (hr) |
| HU (1) | HUE062455T2 (hr) |
| IL (1) | IL277252A (hr) |
| JO (1) | JOP20200233A1 (hr) |
| LT (1) | LT3765447T (hr) |
| MA (1) | MA52008A (hr) |
| MX (1) | MX2020009645A (hr) |
| PE (1) | PE20210926A1 (hr) |
| PH (1) | PH12020551493A1 (hr) |
| PL (1) | PL3765447T3 (hr) |
| PT (1) | PT3765447T (hr) |
| RS (1) | RS64524B1 (hr) |
| SG (1) | SG11202008841VA (hr) |
| SI (1) | SI3765447T1 (hr) |
| TW (1) | TWI818962B (hr) |
| WO (1) | WO2019178510A1 (hr) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663161A (en) * | 1995-02-17 | 1997-09-02 | The Research Foundation Of State University Of New York | Anti-viral triaza compounds |
| WO2002080856A2 (en) * | 2001-04-06 | 2002-10-17 | University And Community College System Of Nevada On Behalf Of The University Of Nevada, Reno | Triaza compound immunoregulatory agents |
-
2019
- 2019-03-15 HU HUE19715609A patent/HUE062455T2/hu unknown
- 2019-03-15 HR HRP20230804TT patent/HRP20230804T1/hr unknown
- 2019-03-15 PL PL19715609.4T patent/PL3765447T3/pl unknown
- 2019-03-15 SI SI201930602T patent/SI3765447T1/sl unknown
- 2019-03-15 CN CN201980032763.5A patent/CN112262129B/zh active Active
- 2019-03-15 MA MA052008A patent/MA52008A/fr unknown
- 2019-03-15 AU AU2019236248A patent/AU2019236248B2/en active Active
- 2019-03-15 WO PCT/US2019/022533 patent/WO2019178510A1/en active Application Filing
- 2019-03-15 LT LTEPPCT/US2019/022533T patent/LT3765447T/lt unknown
- 2019-03-15 CA CA3093972A patent/CA3093972A1/en active Pending
- 2019-03-15 EP EP19715609.4A patent/EP3765447B1/en active Active
- 2019-03-15 RS RS20230647A patent/RS64524B1/sr unknown
- 2019-03-15 US US16/979,457 patent/US11578055B2/en active Active
- 2019-03-15 BR BR112020018767-4A patent/BR112020018767A2/pt unknown
- 2019-03-15 JP JP2020548935A patent/JP2021518337A/ja active Pending
- 2019-03-15 JO JOP/2020/0233A patent/JOP20200233A1/ar unknown
- 2019-03-15 MX MX2020009645A patent/MX2020009645A/es unknown
- 2019-03-15 TW TW108108893A patent/TWI818962B/zh active
- 2019-03-15 SG SG11202008841VA patent/SG11202008841VA/en unknown
- 2019-03-15 PE PE2020002281A patent/PE20210926A1/es unknown
- 2019-03-15 FI FIEP19715609.4T patent/FI3765447T3/fi active
- 2019-03-15 ES ES19715609T patent/ES2953139T3/es active Active
- 2019-03-15 DK DK19715609.4T patent/DK3765447T3/da active
- 2019-03-15 PT PT197156094T patent/PT3765447T/pt unknown
- 2019-03-15 KR KR1020207029261A patent/KR20200133238A/ko active Search and Examination
-
2020
- 2020-09-09 IL IL277252A patent/IL277252A/en unknown
- 2020-09-15 PH PH12020551493A patent/PH12020551493A1/en unknown
- 2020-09-16 CL CL2020002398A patent/CL2020002398A1/es unknown
- 2020-10-06 CO CONC2020/0012484A patent/CO2020012484A2/es unknown
-
2022
- 2022-05-11 US US17/741,989 patent/US20220402891A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210365T1 (hr) | Dna-pk inhibitori | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| AR098912A1 (es) | Inhibidores de syk | |
| PE20142461A1 (es) | Moduladores del receptor de estrogeno y sus usos | |
| AR100340A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| UY37310A (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo | |
| PH12015501934B1 (en) | New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors | |
| AR118124A2 (es) | Proceso para la preparación de un inhibidor de pde4 | |
| GEP20186887B (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| PE20211782A1 (es) | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos | |
| PH12016500643A1 (en) | New octahydro - cyclobuta [1,2-c;3,4-c`] dipyrrol -2- yl | |
| NZ703950A (en) | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds | |
| MA40076A (fr) | Inhibiteurs de syk | |
| AR086318A1 (es) | Piridil aminopiridinas como inhibidores de syk | |
| PA8783001A1 (es) | Acidos benzoilamino-indan-2carboxilicos sustituidos y compuestos relacionados. | |
| PE20110845A1 (es) | Nuevos compuestos heterociclicos nitrogenados, preparacion de los mismos y utilizacion de los mismos como medicamentos antibacterianos | |
| MX2018014358A (es) | Composiciones antimicrobianas. | |
| MX2014013660A (es) | Compuestos antivirales inhibidores del virus de hepatitis c (vhc) ns5b. | |
| WO2015021396A3 (en) | Tricyclic benzoxaborole compounds and uses thereof | |
| AR087017A1 (es) | Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos | |
| NZ720745A (en) | Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide | |
| TN2017000076A1 (en) | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b | |
| PE20170120A1 (es) | Compuestos novedosos de pirimidina sustituidos | |
| PE20190414A1 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
| MX360905B (es) | Polimixinas, composiciones, metodos de preparacion y metodos de uso. |